Coronavirus Update: End Of The Road For Kevzara In COVID-19
Plus: J&J Start Phase I Vaccine Trial In Japan
Sanofi/Regeneron are ending development of Kevzara for COVID-19 after Phase III disappointments. Meanwhile Regeneron is ramping up biologics manufacturing in Ireland as it makes way for COVID-19 antibody production in New York, and multiple vaccines move forward in Japan with new funding and trials.
